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ReviewChronic pain is associated with abnormal excitability of
the somatosensory system and remains poorly treated in
the clinic. Potassium (K+) channels are crucial determi-
nants of neuronal activity throughout the nervous
system. Opening of these channels facilitates a hyperpo-
larizing K+ efflux across the plasma membrane that coun-
teracts inward ion conductance and therefore limits
neuronal excitability. Accumulating research has high-
lighted a prominent involvement of K+ channels in noci-
ceptive processing, particularly in determining peripheral
hyperexcitability. We review salient findings from expres-
sion, pharmacological, and genetic studies that have
untangled a hitherto undervalued contribution of K+chan-
nels in maladaptive pain signaling. These emerging data
provide a framework to explain enigmatic pain syn-
dromes and to design novel pharmacological treatments
for these debilitating states.
The problem of chronic pain
Chronic pain afflicts one in five adults in Europe and many
diseases accompanied by pain are on the rise [1]. The
diverse etiology of chronic pain encompasses trauma,
metabolic or autoimmune disorders, infection, anti-retro-
viral treatment, and chemotherapy. Affected individuals
typically report a combination of incapacitating sensory
abnormalities, including spontaneous pain, hypersensitiv-
ity to stimulation, dysesthesias, and paresthesias. Despite
significant progress, chronic pain remains refractory to
treatment, with only one-third to two-thirds of patients
reporting adequate (>50%) pain relief [1]. Moreover, our
first-line drugs, non-steroidal anti-inflammatory agents
(NSAIDS; e.g., aspirin) and opioids (e.g., morphine), are
associated with adverse dose-limiting side-effects, depen-
dence, and tolerance [2]. The lack of improved treatment
reflects our incomplete understanding of the molecular
pathophysiology underlying these pain states.0166-2236     
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Pain is usually triggered by the activity of specialized
damage-sensing neurons innervating the limbs and torso,
whose cell somata cluster paraspinally in the dorsal root
ganglion (DRG). These pseudo-unipolar cells project axons
that bifurcate into peripheral fibers innervating the skin,
muscle, or other organs, and central fibers that synapse
with second-order spinal cord neurons. A similar architec-
ture is encountered in trigeminal ganglion neurons located
on each side of the cranium, which transduce sensory
information from the face. Based on anatomical, neuro-
chemical, and functional attributes, sensory neurons are
distinguished into small-diameter with unmyelinated C-
fibers, medium-diameter with thinly myelinated Ad-fibers,
and large-diameter that principally give rise to heavily
myelinated Ab-fibers. Because of their ability to encode
noxious mechanical, thermal, or chemical stimuli, C- and
Ad-fibers are considered the main nociceptive afferents
signaling pain. Ab-fibers innervating the skin or muscles
are predominantly low-threshold mechanoreceptive affer-
ents responding to light touch or pressure, although a
proportion are also activated by high-threshold stimuli.
Signals initiated at sensory endings are relayed to the
dorsal horn of the spinal cord and subsequently the brain
via spinal projection systems including the spinothalamic
tract, where the information is evaluated and an appro-
priate response generated. Spinal transmission is not a
passive process but rather involves regulatory spinal pro-
cessing, such as facilitatory or inhibitory modulation by
interneurons, astroglia, and descending pathways, which
can robustly increase or decrease the output [3].
Under normal conditions, generation of action poten-
tials (APs) in sensory nerves typically originates at their
peripheral nerve endings in the presence of a suprathres-
hold stimulus activating specialized receptors. However,
following nerve trauma, electrogenesis can occur sponta-
neously at the site of injury (neuroma), DRG cell body, or
even mid-nerve [4]. Furthermore, inflammation and neu-
ropathic lesions are linked to enhanced responsiveness to
supra- or even subthreshold stimulation [5–7]. This hyper-
excitability is thought to be a major driver of pain and is
ascribed to injury-induced reorganization of membrane ion
channels, which are the principal determinants of AP
generation and propagation. These maladaptive changes
also have downstream effects at the spinal level; C-fiber
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tened responsiveness of spinal cord neurons, such that
innocuous input can now result in abnormally painful
responses (e.g., tactile allodynia after Ab-fiber stimulation)
[8]. In addition, lesioned Ab-fibers can acquire de novo
nociceptive qualities that may also contribute to central
sensitization [9].
Until recently the search for ion channel correlates of
pathological excitability primarily focused on sodium and
calcium channels. Unfortunately, despite significant dis-
coveries in acute and inflammatory pain, no decisive invol-
vement has been definitely established yet, particularly in
neuropathic pain [10]. New evidence however suggests a
previously unappreciated contribution of K+ channels in
chronic pain processing, which we review here.
K+ channels and pain signaling
K+ channels are the most populous, widely distributed, and
diverse class of ion channels in neurons, governed by some
78 genes in humans [11]. Upon activation, K+ channels
facilitate an extremely rapid transmembrane K+ efflux
that can influence AP threshold, waveform and frequency.
Because K+ channel opening repolarizes (or even hyperpo-
larizes) the neuronal membrane, this function can limit AP
generation and firing rate.
Depending on the biophysical profile and precise sub-
cellular localization in sensory neurons, K+ channel con-
duction is postulated to inhibit peripheral excitability by
counteracting AP initiation at peripheral nerve terminals,
reducing conduction fidelity across the axon, or limiting
neurotransmitter release at central terminals (Figure 1).
In addition, although normal sensory transduction does
not rely on cell soma spiking, in chronic pain states K+
channels could provide a brake to the spontaneous activity
developing in the DRG soma or other ectopic loci (e.g., the
neuroma). Indeed, peripheral application of K+ channel
openers on the cell body or terminals invariably decreases
DRG excitability, whereas K+ channel blockers augment
firing [5,11–13]. In the CNS, K+ channel opening could
conceptually lead to enhanced nociception, for instance if
the affected neuron participates in an inhibitory circuit.
Nevertheless, the available data so far indicate that a
variety of antinociceptive drugs mediate their action by
directly opening spinal K+ channels [11].
Based on structural and physiological characteristics,
K+ channels are organized into four distinct groups: vol-
tage-gated, two-pore, calcium-activated, and inward recti-
fying, which we discuss in turn below.
Voltage-gated K+ channels (Kv)
The Kv superfamily is the most numerous among K
+
channels, comprising of 40 genes in humans [14–16]. They
are further classified in 12 families of a subunits that can
interact to form functional homo- or hetero-tetrameric
channels. Members of Kv1-Kv4, Kv7 and Kv10-Kv12 are
pore-forming subunits, whereas Kv5, Kv6, Kv8, and Kv9
members do not form conducting channels unless asso-
ciated with pore-forming subunits (Box 1). Channel tetra-
merization leads to tremendous functional diversity,
further elevated by association with auxiliary b subunits,
splice variants, and post-translational modifications.The largely overlapping pharmacology in neurons sug-
gests a spectrum of Kv currents rather than fixed groups,
reflecting the variant heterotetrameric composition, func-
tional redundancy within families, and complex regula-
tion. The majority of Kv channels are delayed rectifiers,
because they are activated slowly to counteract (rectify)
depolarization. On the basis of biophysical properties and
sensitivity to tetraethylammonium (TEA), a-dendrotoxin,
4-aminopyridine, and muscarinic agonists, Kv currents are
broadly distinguished into sustained delayed rectifying
(IK), transient slowly inactivating (ID), transient fast-inac-
tivating (IA) and non-inactivating (IM) that, as their names
suggest, exhibit different kinetics. Although this classifica-
tion is an oversimplification, it has value as a starting point
to examine the different Kv components in physiological
systems.
These typical currents are also present in dorsal root
and trigeminal ganglia neurons, whereas Gold and collea-
gues described six distinct K+ currents, three of which in
small nociceptors [17–20]. Although it has been known for
some time that nerve injury results in a dramatic decrease
in K+ conductance of peripheral nerves that correlates with
the emergence of hyperexcitability and pain behaviors, it
was not until recently that specific subunits were linked to
these changes [21].
Kv1.1 and Kv1.2 are delayed rectifiers activated by
modest membrane depolarizations, and mainly contribute
to the ID current. In many CNS neurons, these channels
are preferentially localized at the axon initial segment
(AIS, the site of AP initiation in CNS neurons) where they
regulate AP threshold and firing rates, as well as nerve
terminals where they modulate neurotransmitter release
by controlling AP invasion in axonal branches [22,23]. The
dominant role of Kv1 becomes apparent in type 1 episodic
ataxia, where Kv1.1 mutations drive excitability changes
in the cerebellum that cause severe seizures and prema-
ture death [24].
In the peripheral nervous system (PNS), Kv1.1 and
Kv1.2 are predominantly found in the soma and juxtapar-
anodes of medium-large DRG neurons, often in heterote-
tramers [25], and are largely decreased after axotomy
[26,27]; this may contribute to the hyperexcitable pheno-
type. Indeed, Kv1.1 loss-of-function results in reduced fir-
ing thresholds, attenuated mechanical and heat pain, and
increased sensitivity in both phases of the formalin test
[28,29]. By contrast, diminished Kv1.2 activity contributes
to mechanical and cold neuropathic pain by depolarizing
the resting membrane potential (RMP), reducing threshold
current, and augmenting firing rates in myelinated neu-
rons [30]. Moreover, Hao et al. recently reported that Kv1.1
tetramers form a bona fide mechanosensor that acts as an
excitability brake in Ab-mechanoreceptors of mouse DRG,
with a minor contribution of Kv1.2 [31]. Interestingly, this
mechanosensitive current was also detected in some high-
threshold C-mechano-nociceptors (C-HTMRs). Although
the literature highlights predominant Kv1.1 expression
in myelinated neurons, the authors confirmed the presence
of Kv1.1 subunits in a subpopulation of capsaicin-insensi-
tive small neurons and C-fiber terminals in the skin using a
monoclonal antibody [30]. This pattern may correspond to
the occasional expression Rasband et al. documented in147
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Figure 1. Potassium channel activation during action potential (AP) firing in sensory neurons. A depiction of the sequential engagement of different K+ channels during
neuronal activity, and typical effects of K+ channel opening on AP waveform and frequency (inset). The resting membrane potential (RMP) is primarily stabilized by two-
pore K+ (K2P) channels and Kv7 background conductance, whereas KATP channels may also contribute in large neurons [95]. Basal excitability is also influenced by the
opening of low-threshold Kv1 and Kv4 channels which filter out small depolarizations and therefore control the number of triggered APs. Kv4 channels are normally
inactivated at RMP and require prior hyperpolarization (achieved during AP generation) to remove this steady-state inactivation. Once activated, however, Kv4 and other A-
type channels may modulate firing threshold as well as repetitive spiking rate owing to their very fast kinetics [inset (A)] [47]. Following suprathreshold stimulation and
initiation of an AP, high-threshold Kv3 channels open to limit AP duration and ensure quick recovery of voltage-gated Na
+ channels from inactivation [inset (B)]. Kv2
channels are also high-threshold but with much slower activation and inactivation kinetics; they mainly contribute to the repolarizing/after-hyperpolarizing phases and are
hence important for regulating interspike interval and conduction fidelity during sustained stimulation [inset (B)] [38]. Upon neuronal activity, Ca2+-activated K+ channels
are engaged during repolarization (BKCA) and after-hyperpolarization (SKCA) to provide feedback inhibition at nerve terminals by restricting AP duration and thus
neurotransmitter release [(inset (B)]. It is emphasized that this schematic is a simplified representation of most prominent K+ channel contributions to AP firing, based on in
vitro assessment of recombinant counterparts. In vivo, however, the oligomeric composition, association with auxiliary proteins, post-translational modifications, and
regulation by intracellular messengers can yield divergent biophysical properties. K+ channel opening will also have concurrent effects on the function of other ion
channels, for instance by affecting their inactivation. For this reason the combined effect on firing behavior in a physiological context is often hard to predict. Abbreviations:
BKCA, big conductance and SKCA, small conductance Ca
2+-activated K+ channels.
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ences may account for the discrepancy (and multiple spe-
cies variations are recognized), other studies implementing
molecular, immunohistological, and electrophysiological
techniques have also indicated presence of Kv1.1 subunits
in rat small sensory neurons [26,29,32,33]. Intriguingly, an
accumulating body of research indicates that some human
neuropathic pain syndromes are caused by production of
autoimmune antibodies against Kv1 subunits that disrupt
normal A- or C-fiber function (Box 1).Box 1. Pain syndromes associated with autoimmune Kv
antibodies
Compelling evidence suggests that several neurological disorders
linked to peripheral hyperexcitability and pain of a neuropathic
nature, such as neuromyotonia (NMT) or Morvan’s and cramp
fasciculation syndromes, may be caused by erroneous Kv function
due to host production of autoantibodies. Kv antibodies are detected
in approximately 40% of NMT patients [111], and when transferred to
mouse cells they cause reduction of K+ currents, DRG hyperexcit-
ability and other signs of the disease [112]. In agreement with an
autoimmune etiology, immunomodulatory therapy can improve
function and symptoms [113]. Interestingly, these conditions can also
arise owing to autoantibodies against proteins of the functional Kv
complexes, such as Caspr2 or LGI1 [114]. Thus Caspr2 dysfunction
may affect Kv1 assembly at juxtaparanodes, whereas altered Kv1
association with LGI1 in presynaptic C-fiber complexes could explain
symptoms such as heat hyperalgesia. Although still in its infancy, the
concept of Kv complex autoimmunity is an exciting development that
may explain idiosyncratic pain in the absence of injury (e.g.,
fibromyalgia) or other presently enigmatic congenital pain states.
148Most of our knowledge on Kv2 comes from CNS studies,
where Kv2.1 and Kv2.2 conduct the majority of delayed
rectified IK current in several neuron subtypes [15,34]. Kv2
channels are activated slowly after significant depolariza-
tion, therefore their opening primarily influences mem-
brane repolarization and inter-spike hyperpolarization
during AP firing [15]. Importantly, because Kv2 feature
characteristically slow activation and inactivation, the
progressive channel recruitment during sustained activity
can have a cumulative limiting effect on firing rates. The
prominent CNS function of Kv2 is substantiated by specific
localization in dendrites and AIS where the channel can
exert intricate control over somal AP invasion and back-
propagation [35]. Other interesting features of Kv2 are the
phosphorylation-dependent regulation by neuronal activ-
ity, which can fine-tune excitability of CNS neurons by
altering the channel membrane distribution and biophy-
sical properties [36], as well as their modulation by several
silent Kv subunits [37].
Despite the pivotal Kv2 role in shaping CNS signaling, an
involvement in chronic pain was only recently uncovered.
Kv2 subunits are present in small nociceptors (where Kv2.1
conducts the majority of IK [34]) but are also abundantly
expressed in myelinated DRG neurons [38]. Transcript and
protein Kv2 levels are downregulated by traumatic nerve
injury, and this could augment firing by limiting the
Kv2 inhibitory effect on spike frequency [26,27,38].
Indeed, application of a Kv2 blocker on ex vivo DRG pre-
parations promotes myelinated neuron hyperexcitability by
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titive stimulation [38]. It is possible that particular subcel-
lular Kv2 localization forms the basis of an important
filtering capacity (for instance by controlling AP traffic
through the T-junction [39]), similarly to somatodendritic
Kv2 filtering of somatic input in the CNS. Finally, a role in
supraspinal pain pathways has also been demonstrated;
cortical expression of Kv2.2 is reduced in oxaliplatin-induced
neuropathy, and reproducing this in vivo results in marked
cold and mechanical hypersensitivity [40].
All Kv3 channels are high-threshold and are typically
encountered in fast-spiking neurons where they facilitate
AP repolarization and hence dictate AP duration, but
without affecting AP threshold or interspike interval
[41]. Kv3.1 and Kv3.2 are delayed rectifiers contributing
a small fraction (20%) of IK in small nociceptors, with a
possible participation of Kv3.3 heterotetramers [42]. The
Kv3.4 member almost certainly underlies the TEA-sensi-
tive high-threshold transient current detected in nocicep-
tors by Gold et al. (1996). This rapid Kv3.4 current
accelerates nociceptor repolarization, an effect that
restricts Ca2+-dependent neurotransmitter release at cen-
tral nerve endings, where Kv3.4 is localized [41,43]. Hence,
the mechanical hypersensitivity reported after Kv3.4 anti-
sense treatment can be explained by AP broadening and
therefore increased neurotransmission [44], although a
loss of protein kinase C (PKC)-dependent modulation has
also been suggested [43]. It is noted that although APs only
spend a brief time at voltages capable of activating Kv3
channels, this restriction may be overcome by enhanced
Kv3 densities at sites of action [41]. In addition, in native
channels the activation threshold of Kv3.4 could be hyper-
polarized following association with other proteins. For
instance, heterotetramers of Kv3.4 with the delayed rec-
tifiers Kv3.1 or Kv3.2 are activated at –30 mV [45],
whereas Kv3.4 association with the auxiliary MinK-
related peptide 2 (MiRP2) yields subthreshold currents
in skeletal muscle [46].
In addition to Kv3.4, Kv4 members and Kv1.4 also give
rise to transient A-currents (IA) that inactivate rapidly
[15]. In contrast to Kv3.4, these A-channels are activated
by small depolarizations, and their function in DRG can
limit AP threshold, duration, and firing frequency [47].
Two low-threshold IA are detected in DRG neurons [17];
although Kv1.4 might contribute to the low-threshold IA in
small DRG neurons, the fast voltage-dependent recovery
from inactivation suggests the presence of Kv4 channels
[25]. Therefore the low-threshold component may be pre-
dominantly mediated by Kv4.1, and the somatically con-
fined Kv4.3 [48], because Kv4.2 is either absent or
expressed at very low levels [27,48]. Consistent with a role
in nociceptive pathways, A-type subunit expression and
currents in the DRG are found to be reduced in a variety of
pain models [21,25,44,49]. Mimicking Kv4.3 downregula-
tion via intrathecal antisense is sufficient to induce
mechanical hypersensitivity in naı¨ve rats, presumably
via reducing firing thresholds in a subset of Mrgprd
(Mas-related G protein-coupled receptor D) neurons [44].
A-type blockers or short interfering RNA (siRNA) treat-
ment can also diminish the analgesia by diclofenac in bone
cancer [49], although K+ channel-related antinociceptionby this drug may be principally conferred via direct open-
ing of other voltage-gated (e.g., Kv7 [50]), ATP-sensitive, or
Ca2+-activated channels [51]. Finally, despite its negligible
involvement in DRG excitability, Kv4.2 can strongly mod-
ulate pain plasticity in dorsal horn neurons; thus Kv4.2-
null mice exhibit quicker mechanical pain resolution fol-
lowing nerve injury, as well as loss of extracellular signal-
regulated kinase (ERK)-dependent sensitization in inflam-
matory models [52]. Although a few Kv4 activators are
available (e.g., NS-5806 and KW-7158), the pacemaking
activity of Kv4 channels in cardiac tissue is limiting for
systemic applications.
Kv7 channels open near RMP and underlie the low-
threshold, non-inactivating M-current (IM) [20]. IM serves
as a native ‘voltage clamp’ that stabilizes RMP and reg-
ulates AP threshold and accommodation within AP trains,
affording it a central role in modulation of neuronal excit-
ability. Accordingly, mutations in the human Kv7.2/Kv7.3
encoding genes cause benign familial neonatal epilepsy
due to excessive excitability in distal motor axons [20]. In
the DRG, IMmediated by Kv7.2, Kv7.3 and Kv7.5 oligomers
is the dominant subthreshold K+ current in small neurons
and a significant component in larger neurons (together
with Kv1.1/Kv1.2) [12]. Kv7.2 and Kv7.3 are enriched in
nociceptor AIS and terminals (but see [53]) and in nodes of
myelinated fibers, in contrast to the majority of Kv chan-
nels which occupy paranodes or juxtaparanodes [12,53].
Kv7.2 and associated currents are reduced in DRG follow-
ing neuropathic lesions, although the delayed onset of
downregulation suggests a link to the maintenance rather
than initiation of pain [54]; nevertheless, enhancement of
residual IM can reverse pain behaviors [55]. Reduced Kv7
function is also involved in inflammatory pain, where IM
inhibition occurs via protease-activated receptor 2 (PAR2)
activation and phospholipase C (PLC)-induced depletion
of phosphatidylinositol-4,5-bisphosphate (PIP2), inositol
trisphosphate (IP3)-mediated Ca
2+ augmentation, or a
combination of both [12]. Consistent with this, PLC acti-
vation by bradykinin results in Ca2+ release which inhibits
IM, thus allowing Ca
2+-activated Cl channels to amplify
depolarizing input and trigger spontaneous firing [56].
The general purpose anti-inflammatory diclofenac has
also been shown to directly activate Kv7.2/Kv7.3 channels
[50].
The anticonvulsant retigabine, the most advanced Kv
modulator, reduces excitability of animal [12,57,58] and
human [59] axotomized nociceptive fibers by enhancing IM
via a hyperpolarizing shift in Kv7.2/Kv7.3 activation.
Accordingly, both retigabine and its structural analogue
flupirtine (used as an analgesic in Europe since 1984) are
antinociceptive in a variety of inflammatory and neuro-
pathic pain paradigms through both central and peripheral
mechanisms [12,60–62]. Although retigabine failed to pro-
duce analgesia in a recent clinical trial of post-herpetic
neuralgia, flupirtine is currently in Phase II trials for
fibromyalgia pain. New activators such as the Kv7.2/
Kv7.3-selective ICA-27243 are in the pharmaceutical pipe-
line because retigabine and flupirtine do not show strong
selectivity among Kv7 subunits and can additionally cause
side-effects by interacting with other targets such as GABA
receptors [63].149
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K2P have emerged as promising candidates for pain mod-
ulation owing to their cell type-specific expression and
lower inter-family sequence identity. They are unique
among K+ channels in that they contain two pore domains
and co-assemble as dimers rather than tetramers. Under
physiological conditions K2P generate hyperpolarizing leak
currents that stabilize cells below firing threshold, and
disrupting this constitutive conductance results in depo-
larization and increased excitability [64]. Sensory neurons
express many of the 15 members of the K2P superfamily,
including TWIK1 (two-pore weak inwardly rectifying K+
channel), the TWIK-related (TR) channels TRESK,
TREK1, and TRAAK, as well as TASK1 (acid-sensitive
K+ channel), and marked reductions have been documen-
ted in pain states [65,66]. The importance of K2P in pain is
highlighted by the discovery of a human K+ channelopathy;
thus, familial migraine with aura is associated with a
dominant-negative mutation in TRESK, a subunit strongly
expressed in human trigeminal and dorsal root ganglia
[67]. This fits well with the fact that migraine is associated
with secretion of neuropeptides such as calcitonin gene-
related peptide (CGRP) and substance P by meningeal
nociceptors of the trigeminal ganglia, which may lead to
sensitization. In a traumatic injury context, TRESK
expression is decreased by axotomy, whereas pharmaco-
logical or siRNA inhibition induces C-fiber hyperexcitabil-
ity and pain behaviors [68]. Contrarily, adenovirus-
mediated spinal delivery of TRESK can reverse nerve
injury-induced mechanical allodynia [69]. Another inter-
esting but relatively unexplored member, TWIK1, is selec-
tively expressed in medium-large DRG neurons and
undergoes robust and persistent reductions by neuropathic
injury [66].
A particularly noteworthy feature of K2P channels is
their activation by a wide range of physicochemical factors
including volatile anesthetics [70]. For instance, TREK1 is
coexpressed with TRPV1 in nociceptors and can be acti-
vated by heat, stretching or lipids; a corresponding current
is recorded in small neurons from wild type, but not
TREK1 knockout (KO) animals [71]. TREK1 KO animals
also show increased sensitivity to heat and mechanical
stimulation, suggesting that normal K2P function counter-
balances inward currents generated by TRPV1 and
mechanosensitive Na+-permeable channels, respectively.
Interestingly, TREK1 activity is decreased by inflamma-
tory mediators such as prostaglandin E2 (PGE2) and lyso-
phosphatidic acid, and TREK1-null mice develop more
modest mechanical and thermal hyperalgesia during
inflammation, presumably due to loss of this inhibition
[71,72]. These data suggest that TREK1-modulating
drugs may be useful in acute and inflammatory pain.
Although TREK1 KOs show reduced cold pain after
SNL, the precise involvement of this channel in neuro-
pathic pain has not been thoroughly examined [71]. The
member TRAAK is also mechano- and heat-sensitive, and
simultaneous deletion of TREK1 and TRAAK has additive
effects that may explain some of the mechano-hypersen-
sitivity in colitis [73,74]. Furthermore, double TREK1/
TRAAK KOs exhibit defects in acute cold pain processing,
traced back to menthol-insensitive nociceptors [74].150Interestingly, oxaliplatin reduces TREK1 and TRAAK
expression, and double KOs have modified cold pain
responses in this model [75].
Ca2+-activated K+ channels (KCA)
Opening of KCA during neuronal firing hyperpolarizes the
membrane and provides feedback inhibition that limits
Ca2+ influx and excitability, making them powerful regu-
lators of synaptic transmission at nerve terminals [11].
Based on their conductance, they are further divided into
BKCA (big conductance), IKCA (intermediate conductance),
and SKCA (small conductance).
All KCA are found in DRG and respond to increases in
intracellular calcium, whereas BKCA are also voltage-sen-
sitive [76,77]. Big conductance KCA are thought to influ-
ence excitability more prominently; illustrative of their
significance in pain transduction is the recent finding of
a functional coupling with TRPV1 (transient receptor
potential cation channel, subfamily V, member 1) in noci-
ceptors [78]. Blocking these channels with iberiotoxin
reduces outward currents, prolongs AP duration, and
increases firing rates in small-medium sensory neurons,
with no effect on RMP, AP threshold, or AP amplitude [77].
Accordingly, axotomy decreases BKCA expression and
Ca2+-dependent post-spike after-hyperpolarization in
small-medium DRG neurons [79]. Contrariwise, the spe-
cific BKCA opener NS-1619 suppresses DRG neuron firing
and can even antagonize the hyperexcitability evoked by A-
channel block [77]. Interestingly, PGE2 and other inflam-
matory mediators reduce BKCA channel activity in noci-
ceptors [17,76,80] and BKCA deletion in these neurons
enhances inflammatory pain without affecting acute or
neuropathic behaviours [133]. The BKCA opener andolast
is currently in Phase III trials as an anti-inflammatory for
chronic obstructive pulmonary disease; it would be inter-
esting to evaluate the antinociceptive properties of NS-
1619 and andolast in chronic pain models.
Smaller conductance KCA are detected in a mixture of
human and rodent DRGs, and may also contribute to pain
phenotypes [76,81]. In small neurons, SKCA are down-
stream targets of NMDA receptor (NMDAR)-mediated
Ca2+ influx because deleting the NR1 subunit in DRG
induces hyperexcitability and pain hypersensitivity that
can be reproduced by NMDAR antagonism or pharmaco-
logical SKCA inhibition [82]. Although IKCA expression in
large neurons is decreased by nerve injury, SKCA and IKCA
subunits in small neurons appear unaltered, suggesting
that opening these channels may be a viable approach for
chronic pain relief [76]. In line with this, the channel
opener 1-ethyl-2-benzimidazolone (1-EBIO) reduces excit-
ability in response to mechanical stimulation; however, the
analgesic properties of such compounds remain to be
robustly tested [11,83].
KCA also participate in central pain processing. Nerve
injury leads to enhanced BKCA expression in second-
order neurons near the dorsal root entry zone, and acti-
vating these channels by intrathecal NS-1619 reverses
pain hypersensitivity [79]. Conversely, KCA blockers can
antagonize the antinociceptive effects of muscarinic
receptor agonists, gabapentin, and perhaps some
NSAIDS [11].
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These channels are expressed mainly (but not exclusively)
in supporting cells (Box 2) and can conduct atypical inward
(rather than outward) K+ currents at depolarized mem-
brane potentials. This buffering activity adds to glial K+
uptake through electrogenic Na+/K+ pumps to offset extra-
cellular K+ accumulation during neuronal firing [84], thus
preventing AP ‘short-circuiting’ and uncontrolled excitabil-
ity changes [85]. They belong to one of seven families (Kir1-
Kir7) and have a relatively simple structure with two
transmembrane domains flanking the pore region [11].
Three families implicated in nociception are Kir3 (also
known as G protein-regulated inward rectifiers K+ chan-
nels, GIRK), Kir2, and the ATP-sensitive channels (KATP).
Neuronal GIRK channels are important determinants
of spinal analgesia. As their name suggests they can
interact with G proteins, an association thought to under-
lie the analgesic effects of opioids, endocannabinoids, and
endogenous pain modulators [11]. Interestingly, enhanced
GIRK1 phosphorylation in the dorsal horn following neu-
ropathy or inflammation suggests reduced channel activity
[86], whereas ‘pain risk’ GIRK2 alleles are associated with
intensity of chronic back pain in humans [87]. Although no
GIRK openers are currently available, their development
could provide a viable alternative to opiates because this
interaction may set in motion the same analgesic pathway
without the unwanted side-effects of direct opioid activa-
tion [88–90]. Furthermore, a recent study suggests that
GIRK2 expressed in sensory neurons also contribute to
peripheral opioid-mediated antinociception [134]. Finally,
although normally expressed in low levels in the periphery,
Kir2.1 channels could also be useful for therapeutic inter-
ventions; virus-mediated expression of Kir2.1 in DRG neu-
rons can restore excitability following compression injury,Box 2. The involvement of glial K+ channels
Accumulating evidence points towards a pain-modulating role of K+
channels in satellite glial cells (SGC). For example, an inward current
is detected in SGC of the trigeminal ganglion. The member
responsible appears to be Kir4.1 because no inward currents are
detected in Kir4.1-null animals, alongside depolarized RMP and
inhibition of K+ uptake [115,116]. Attenuation of Kir4.1 expression in
SGC of the trigeminal ganglion by neuropathic lesions or antisense
treatment results in spontaneous and evoked facial pain-like
behaviors [117]. Similarly, CFA inflammation can suppress Kir4.1
expression and associated currents, leading to depolarized RMP
[118]. In the spinal cord, nerve injury reduces expression of Kir6.1/
SUR, whereas the KATP opener cromakalim relieves pain via
regulation of astroglial gap junctions [119]. Put together, these
studies suggest that heightened extracellular K+ due to impaired
glial K+ homeostasis can cause downstream hyperexcitability of
adjacent neurons, although a glutamate involvement is also
plausible. Interestingly, Kir2.1, Kir2.3, and Kir6.2 are also present in
Schwann cells at the nodes of peripheral nerves, and putative
regulation by injury might regulate excitability of myelinated
neurons in a similar fashion [94,120]. Another class of K+ channels
involved in spinal SGC-dependent hyperexcitability are the micro-
glia-expressed KCA, which participate in microglia activation and
migration following injury [121]. Hence, intrathecal treatment with a
BKCA blocker inhibits P2X4 expression and BDNF synthesis in spinal
microglia, and precludes injury-induced tactile allodynia. The
analgesic effects of ketamine in neuropathic pain and inflammation
may also be partly mediated via inhibition of microglia activation
following KCA current attenuation [121].and even preclude pain symptoms when applied pre-emp-
tively [91].
KATP members are tetramers of Kir6.1 or Kir6.2 sur-
rounded by four sulfonylurea receptor subunits (SUR1 or
SUR2) [92]. These channels are inhibited by ATP but also
modulated by ligands such as ADP, adenosine, NO, vasoac-
tive intestinal polypeptide (VIP) and CGRP. KATP currents
are generally thought to play a minor role in setting basal
excitability of DRG neurons, where Kv7 and K2P conduc-
tances dominate [93]. However, a therapeutic potential in
pathological conditions has been proposed. Thus, although
Kir6.2 activity is reduced in large DRG neurons post-injury,
the ability of KATP openers to hyperpolarize RMP is
retained, which could be exploited for neuropathic pain
treatments [94,95]. Similarly, the inhibition of Kv7 activity
in nociceptors during inflammation may also reveal
analgesic roles for KATP channels. Indeed, the activators
pinacidil and diazoxide reduce the hyperexcitability and
pain induced by a range of peripheral inflammatory stimuli
[51,93,96].
Finally, KATP opening in the CNS is linked to the
antinociception produced by systemic treatment with mor-
phine, NSAIDs, or even gabapentin [11,97]. Unfortunately,
the involvement of KATP in modulation of cardiac rhyth-
micity, pancreatic insulin secretion, and intestinal func-
tion necessitates therapeutic strategies that selectively
target the tissues of interest [92].
How does nerve injury trigger K+ channel dysfunction?
In the preceding paragraphs we reviewed studies describ-
ing distinct expression patterns of K+ channels involved in
the peripheral and central processing of painful stimuli
(Figure 2) as well as their extensive downregulation after
nerve lesions (Table 1). The latter finding has implications
for treatment because the analgesia produced by pharma-
cologically enhancing the remaining K+ activity may be of
limited scope. In these cases, targeting upstream cascades
that orchestrate K+ channel dysfunction could yield more
efficacious treatments. For instance, it was recently
reported that an injury-induced endogenous non-coding
RNA attenuates Kv1.2 expression, and blocking this path-
way diminishes neuropathic pain [30]. Whether similar
non-coding RNAs modulate the activity of other K+ chan-
nels is a question that warrants further investigation.
Similarly, expression of Kv7.2, Kv4.3, and other ion chan-
nels in DRG is inhibited by the transcription factor REST
(RE1-silencing transcription factor), which is induced by
injury or inflammation [54,98]. Accordingly, blocking
REST with antisense restores transcript levels and
reverses some neuropathic pain symptoms [99].
Ion channel expression is typically controlled by care-
fully balanced neurotrophic support, which may become
disrupted in pain pathology [100]. One of the most inter-
esting messengers downstream of REST is brain-derived
neurotrophic factor (BDNF), which has an established
sensitizing role; in a diabetic neuropathy model, pre-emp-
tive anti-BDNF treatment can reverse the IA reduction in
myelinated neurons [101]. The regulatory role of BDNF
may be more general among K+ channels, because the
injury-induced BKCA downregulation in DRG can also be
reversed by anti-BDNF [102]. There is also evidence that151
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Figure 2. Expression and function of K+ channels in sensory neurons. (A) Subcellular localization of K+ channel subunits in unmyelinated (top) and myelinated (bottom) murine
dorsal root ganglia (DRG) neurons. The panoply of K+ channels endows sensory neurons with a sophisticated machinery for the regulation of neuronal excitability. The depiction
illustrated here is not absolute but rather reflects most prominent expression patterns in pain-relevant subpopulations, as reported in the literature. In addition, it is noted that K+
channel distribution patterns can vary tremendously between species, and validation against human data is currently very limited [59,81]. In the pain pathway, the TWIK-related
(TR) channels TREK1 and TRAAK (and possibly TRESK) located at C-fiber terminals can counteract the activation of inward-conducting ion channels by pressure, heat or cold,
whereas steady Kv7 currents also stabilize RMP and regulate action potential (AP) threshold. In myelinated neurons, low-threshold Kv1.1/Kv1.2 heterotetramers appear to
modulate acute and neuropathic pain modalities [28,30,31], whereas Kv1.4 and Kv4 members may exert similar roles in small nociceptors [25,44]. In addition, recent evidence
suggest that Kv1.1/Kv1.2 may also function as mechanoreceptors in some C-fibers (not shown) [31]. Transmission of signals generated at the periphery is reliant on numerous
axonal K+ channels, which influence the fidelity of AP conduction and therefore the fiber following frequency. Although normal sensory transduction is independent of spiking in
the DRG soma, this can become a site of spontaneous firing in neuropathic conditions. In these scenarios, the activity of somal K+ channels may become an important regulator
of excitability by influencing somal AP generation as well as propagation past the DRG T-junction. Potential candidates here are channels that preferentially localize at the soma
or axon initial segments (in grey), such as Kv4.3 in mechanosensitive C-fibers [44] or Kv2/Kv9.1 in A-fibers [38,122]. At the central terminals, Ca
2+-activated channels BKCA fine-
tune activity and regulate neurotransmitter release in the spinal cord in response to calcium influx during AP firing. The high-threshold Kv3.4 limits AP duration and thus may
play a key role in synaptic transmission, whereas Kv1.2 may also regulate presynaptic terminal excitability [22]. Finally, pain processing can be influenced by K+ channels
expressed by glial satellite cells (GSC) in the dorsal horn. Astrocyte-expressed Kir6.1 (and perhaps Kir3.1 [86]) buffers the extracellular K
+ to maintain equilibrium potential during
neuronal firing [119], and BKCA conduction is involved in microgliosis following injury [121]. In addition, satellite cell-expressed Kir4.1 is involved in facial pain processing in the
trigeminal ganglion (not shown). Subunits denoted in italics represent localizations that are indirectly implied by pharmacological profiling in DRG neurons, or by extrapolating
on known localization in other neuronal types. For example, the Kv1.1 and Kv1.2 subunits are typically detected in dendrites and terminals of CNS neurons [22,23], whereas
TREK1 and TRAAK are axonally trafficked in sciatic nerves and are present at synaptic sites in cerebellar cultures [123]. (B) K+ channel composition of a myelinated DRG axon,
illustrating nodes, paranodes, juxtaparanodes (JPN), internode segments, and a myelinating Schwann cell. The Kv7.2 and Kv7.3 subunits (together with a splice variant of Kv3.1)
are found in the nodes, and may therefore more prominently affect saltatory conduction under physiological conditions. Following axonal injury and demyelination, however,
other channels such as the juxtaparanodal Kv1 subunits may become exposed, leading to reduced conduction velocity and negative symptoms including sensory loss. In other
cases, reduced axonal K+ channel function due to disrupted node organization (e.g., autoantibodies against Kv complex proteins) may induce peripheral hyperexcitability.
Schwann cells also express inward rectifiers that regulate the node microenvironment during neuronal activity.
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Table 1. Summary of studies investigating the effect of altered K+ channel expression and function on acute, neuropathic, and
inflammatory pain phenotypes
Superfamily Subunit Manipulation Expression/excitability
changes
Pain phenotype Comments Refs
Voltage-
gated
Kv1.1 KO transgenic Loss of IKmech currents
#Mechanical threshold
(HTM-C fibers)
#Firing adaptation (Ab-
fibers)
"Mechanical
"Heat
"Formalin
Reduced morphine
antinociception
[28,31]
Morvan’s syndrome
Neuromyotonia
"Peripheral excitability "Mechanical allodynia
"Heat hyperalgesia
Autoantibodies to Kv1
complexes; cause
disease when
transferred to cells;
immunomodulatory
therapy useful
[111–113]
Kv1.2 Nerve injury (SNL)
Kv1.2 knockdown
#K+ current, #firing
threshold
"RMP, "firing rate
"Mechanical
"Cold
SNL induces Kv1.2
antisense RNA; pre-
emptive sense RNA
alleviates pain
[30]
Kv1.4 Nerve injury (SNT,
SNL)
Diabetic neuropathy
Inflammation
#Kv1.4 expression ND – [25,101,124]
Kv2.1 Nerve injury (SNL,
SNT)
#Kv2.1 expression ND – [26,38]
Kv2.2 Nerve injury (SNL, CCI) #Kv2.2 expression ND – [27,38]
Oxaliplatin
Kv2.2 knockdown
(cortex)
#Kv2.2 expression
(cortex)
"Mechanical
"Cold
– [40]
Kv3.4 Nerve injury (SNL)
Kv3.4 knockdown
Diabetic neuropathy
#Kv3.4 expression
"AP duration
"Mechanical PKC phosphorylation
slows Kv3.4 inactivation
and decreases AP
duration
[43,44,101]
Kv4.2 KO transgenic DH neurons: "RMP,
#firing threshold
"Repetitive firing
#IA current,"excitability
"Mechanical, "heat
#Formalin,
#Carrageenan
Quicker resolution of
mechanical allodynia
after CCI; defects in
central sensitization
[52]
Kv4.3 Nerve injury (SNL)
Diabetic neuropathy
Kv4.3 knockdown
#Kv4.3 expression "Mechanical REST antisense blocks
Kv4.3 downregulation
[44,99,101]
Kv7.2
Kv7.3
Nerve injury (PSNL) #Kv7.2 expression
#IM current
"Mechanical
"Heat
Perisciatic flupirtine
reverses pain;
antagonized by XE-991
blocker
[54]
Bone cancer #IM current,
"excitability
"Mechanical
"Heat
– [55]
Retigabine (opener)
after nerve injury or
inflammation
#Excitability
(DRG, neuroma, DH
neurons)
#Mechanical (CCI, SNI,
bone cancer)
#Heat (bone cancer)
#Cold (CCI)
#Formalin,
#Carrageenan #CFA
#Visceral pain
Antinociception
reversed by XE-991; no
effect on intact fibers or
acute pain
[12,55,58,
60–62]
Kv9.1 Kv9.1 knockdown
Nerve injury (SNL)
#Kv9.1 expression
"SA, "firing, "after-
discharge
"Mechanical Mediated through Kv2 [122]
Human SNPs ND "Risk of phantom limb
pain
"Risk of chronic back
pain
"HIV neuropathy pain
intensity
– [125,126]
Two-pore TRESK Human DN mutation #TRESK currents "Migraine pain – [67]
Nerve injury (SNT)
TRESK knockdown
#TRESK expression "Mechanical Trend for thermal pain [68]
TRESK overexpression
after nerve injury (SNI)
"TRESK expression #Mechanical allodynia – [69]
TREK1 KO transgenic #TREK1 expression
"AP firing
"Mechanical, "heat
#Inflammatory
Reduced cold
hypersensitivity after
[71]
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Table 1 (Continued )
Superfamily Subunit Manipulation Expression/excitability
changes
Pain phenotype Comments Refs
SNL; TREK1 inhibited
by PGE2 and cAMP
TRAAK KO transgenic #TRAAK expression "Mechanical, "heat TREK1/TRAAK KO:
"noxious cold pain but
reduced cold sensitivity
after oxaliplatin
[74,75]
TASK Inflammation (CFA) #TASK1, TASK2, TASK3
expression
ND – [65]
TWIK1 Nerve injury (SNI) #TWIK1 expression ND – [66]
Inward
rectifiers
Kir2.1 Nerve injury (CCD) plus
Kir2.1 overexpression
"Kir2.1 expression
#RMP, "firing
threshold, #SA
#Mechanical
hyperalgesia
Late treatment had no
affect
[91]
Kir3.1 Nerve injury (PSNL)
Inflammation
(formalin)
"Phospho-Kir3.1 (SC) ND Predicted to increase
excitability by
decreasing Kir3.1
activity
[86]
Kir3.2 Eight human SNPs ND #Acute pain tolerance
"Chronic back pain
intensity
– [87]
Kir4.1 Nerve injury (CCI)
Kir4.1 knockdown
#Kir4.1 expression (SGC
of TG)
"Facial pain – [117]
Inflammation (CFA) #Kir4.1 expression (SGC
of TG)
#Kir4.1 currents, "RMP
(SGC of TG)
"Facial pain – [118]
KATP Nerve injury (CCI) #Kir6.1 expression (SGC
of spinal cord)
"Mechanical, "heat Cromakalim (opener)
reversed pain;
antagonized by
carbenoxolone
[119]
Nerve injury (SNL) #Kir6.2 expression
(DRG, Schwann cells)
#KATP activity
"Mechanical Diazoxide (opener) or
CAMKII activate
residual KATP channels
[94,95]
Pinacidil and diazoxide
(openers)
#DRG excitability #Inflammatory
#Mechanical, #thermal
Antagonized by KATP
blocker glyburide
[93]
Calcium-
activated
SKCA/IKCA Apamin (blocker) "AP frequency,
"excitatory
transmission
"Mechanical, "heat NR1 KO in DRG has
same effects
[82]
Nerve injury (CCI)
Inflammation (CFA)
No change in SK1–3
expression
ND Targeting residual SK
may be
viable for pain
treatment
[76]
Nerve injury (avulsion) #IK1 expression ND IK1 was upregulated in
vitro by NT-3
[81]
1-EBIO (opener) #Excitability after
mechanical stimulation
ND Effects reversed by
UCL-1848 (blocker)
[83]
BKCA Iberiotoxin (blocker) #BKCA current
"AP duration, "firing
frequency
ND NS-1619 (opener)
decreases excitability
[77]
Nerve injury (SNL) DRG: #BKCA expression
SC: "BKCA expression
(DREZ)
"Mechanical, "heat Iberiotoxin reduces
mechanical thresholds;
BKCA opener (NS-1619)
reverses SNL pain
[79]
Nerve injury (SNL) #BKCA current (DRG)
# BKa1 mRNA (DRG)
ND BDNF reduced BKCA
currents.
Anti-BDNF reversed
BKCA reduction
[102]
Inflammation (CFA) #BKCA current (DRG) ND No change in BKCA
expression
[80]
Charybdotoxin
(blocker)
#P2X4 and BDNF in
microglia
#Tactile allodynia Mediated via inhibition
of microglial activation
[121]
KO transgenic #BKCA expression
(nociceptors)
"Inflammatory Acute and neuropathic
pain unaffected
[133]
Unless stated otherwise, entries in expression and excitability refer to sensory neurons. Abbreviations: AGJ, astroglial gap junction; AP, action potential; CCD, chronic
compression of the dorsal root ganglion; CFA, complete Freund’s adjuvant; CCI, chronic constriction injury; DH, dorsal horn; DN, dominant-negative; DREZ, dorsal root entry
zone; DRG, dorsal root ganglion; HTM, high-threshold mechanoreceptor; KO, knockout; ND, not determined; PSNL, partial sciatic nerve ligation; RMP, resting membrane
potential; SA, spontaneous activity; SC, spinal cord; SGC, satellite glial cells; SNI, spared nerve injury; SNL, spinal nerve ligation; SNP, single-nucleotide polymorphism;
SNT, sciatic nerve transection; TG, trigeminal ganglion.
Review Trends in Neurosciences March 2014, Vol. 37, No. 3
154
Box 3. Why so many silent and auxiliary Kv subunits?
Emerging evidence suggests that the rich complement of modulatory
Kv partners may have previously overlooked significance in fine-tuning
neuronal activity. The silent Kv9.1 subunit is selectively localized in
myelinated DRG neurons, the principal source of spontaneous activity
after nerve injury [5]. Injury-induced Kv9.1 downregulation triggers
spontaneous and evoked hyperexcitability as well as mechanical
allodynia [122]. Intriguingly, a human Kv9.1 polymorphism is asso-
ciated with high risk of developing chronic back pain or persistent pain
after amputation [125], whereas another study found a link with pain
intensity in HIV neuropathy [126]. These effects are most likely
mediated via a regulation of Kv2 currents, which are modulated by
Kv9.1 in vitro [37]. Similar Kv2 modification by the non-conducting
Kv5.1, Kv6.1, Kv6.3, Kv8.1, and Kv9.3 has been reported in heterologous
systems and DRG neurons; it is therefore appealing to suggest that
silent subunits might be instrumental in pain pathophysiology [34,37].
Auxiliary proteins can modulate Kv function by affecting gating,
expression levels and trafficking. For instance, Kvb2 subunits enhance
Kv1 currents by promoting trafficking and membrane incorporation as
well as inhibiting inactivation, whereas Kvb1 subunits confer the
opposite effects [127]. Genetic Kvb2 deletion leads to defects in axonal
targeting of Kv1.1 and Kv1.2, reduced after-hyperpolarization, and
increased amygdala hyperexcitability associated with memory im-
pairments [128]. In myelinated DRG neurons, Kvb2.1 colocalizes with
Kv1.1 and Kv1.2; however, the modest Kvb2.1 reduction by injury
(25%) argues against a significant role in Kv1 dysfunction in chronic
pain [25,26]. Nevertheless, targeting auxiliary subunits may be of
therapeutic value; for example Kv1.1 ‘disinactivators’ reduce excit-
ability by preventing Kv1.1 inactivation by Kvb1 [129].
Similarly, the localization of AMIGO (amphoterin-induced gene and
ORF) dynamically follows that of Kv2.1, and AMIGO increases Kv2.1
conductance [130]. Kv4 surface expression and gating can be
enhanced by Kv channel interacting proteins (KChIPs), which respond
to intracellular calcium fluxes during AP firing, and by dipeptidyl-
peptidase-like proteins (DPPs) [131]. Interestingly, these auxiliary
proteins often have distinctive distributions that may be relevant to
pain processing. For instance, KChIP3 is abundant in medium-large
DRG neurons, whereas DPP10 is restricted to small neurons [132].
Finally, Kv7.2/Kv7.3 can be modulated by MinK-related peptides
(MiRPs, pluripotent proteins that also interact with Kv2, Kv3, and
Kv4), calmodulin, and A-kinase anchor proteins (AKAPs) [131]. The
above description is by no means exhaustive; interested readers are
referred towards excellent topical reviews [131].
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(NGF), glial-derived neurotrophic factor (GDNF), and neu-
rotrophin 3 (NT3) [81,103,104]. Early research showed
that NGF treatment can normalize axotomy-induced IA
and IK reductions in DRG; however, an inhibitory effect on
IA and IM may occur during inflammation [105–107]. The
exact influence of these growth factors and the responsive
K+ channel subunits remains to be systematically tested
and clarified.
Concluding remarks
The exceptional abundance and breadth of function
encountered in K+ channels has complicated efforts to
untangle explicit roles in pain syndromes. Owing to
advances in molecular, biochemical, electrophysiological,
and genetic methods, however, we can now appreciate the
involvement of specific subunits in maladaptive pain sig-
naling after injury or inflammation. Nevertheless, there
are many potential avenues of K+ involvement that have
hardly been explored. It seems likely that unknown muta-
tions in K+ channel genes might contribute to inherited
pain syndromes. There are many ‘silent’ K+ channel sub-
units for which we have little idea of whether and how they
might affect pain processing (Box 3). Auxiliary subunits
can provide alternative substrates for pharmacological
modulation; however, our understanding of these interac-
tions in the PNS is also limited. In many chronic pain
models an extensive dysregulation of several K+ channels
is seen, and it is unknown whether a common epigenetic
control exists.
Manipulation of K+ channel subunits with dominant
contributions in neuron excitability is likely to play a key
role in shaping future pain treatments. The development of
novel technologies and increasing availability of structural
information creates an optimistic outlook for pharmacolo-
gical design of K+ channel modulators [108–110]. In the
next few years these advancements may be complemented
by gene therapy strategies to introduce K+ channel copies
at lesioned sites of the nervous system. Given the consider-
able convergence of pain mechanisms, it is plausible thatsynergistic treatments with K+ channel openers and other
drugs (e.g., sodium or calcium channel blockers) can
improve analgesic outcomes and/or circumvent side-effects
by expanding the therapeutic window of present drugs to
lower, more tolerable doses.
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